Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Alnylam Pharmaceuticals, Inc. ALNY
$206.27
+$0.18 (0.09%)
На 18:00, 12 мая 2023
+2.84%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
25672280160.00000000
-
week52high
242.97
-
week52low
120.43
-
Revenue
1037418000
-
P/E TTM
-23
-
Beta
0.47820000
-
EPS
-9.29000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Buy | Buy | 04 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 04 авг 2022 г. |
| Chardan Capital | Buy | Buy | 04 авг 2022 г. |
| BMO Capital | Market Perform | Market Perform | 04 авг 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 29 июл 2022 г. |
| Oppenheimer | Outperform | Outperform | 09 сент 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 09 сент 2022 г. |
| BMO Capital | Market Perform | Market Perform | 09 сент 2022 г. |
| RBC Capital | Outperform | Outperform | 20 сент 2022 г. |
| Jefferies | Buy | Buy | 03 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 13 окт 2022 г. |
| JP Morgan | Neutral | Neutral | 24 окт 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 02 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 28 окт 2022 г. |
| Goldman Sachs | Buy | Buy | 28 окт 2022 г. |
| Barclays | Overweight | Overweight | 28 окт 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 07 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 16 дек 2022 г. |
| Canaccord Genuity | Buy | 18 янв 2023 г. | |
| SVB Leerink | Market Perform | Market Perform | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Tanguler Tolga | D | 0 | 953 | 03 февр 2023 г. |
| Tanguler Tolga | D | 953 | 1293 | 03 февр 2023 г. |
| Tanguler Tolga | D | 2246 | 865 | 03 февр 2023 г. |
| Tanguler Tolga | D | 3111 | 185 | 03 февр 2023 г. |
| Tanguler Tolga | D | 3296 | 128 | 03 февр 2023 г. |
| Franchini Indrani Lall | D | 3500 | 5 | 02 февр 2023 г. |
| Franchini Indrani Lall | D | 3505 | 586 | 02 февр 2023 г. |
| Franchini Indrani Lall | D | 4091 | 1007 | 02 февр 2023 г. |
| Franchini Indrani Lall | D | 5098 | 77 | 02 февр 2023 г. |
| Tanguler Tolga | D | 3424 | 4 | 02 февр 2023 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3235830 | -34618 | 31 авг 2020 г. |
| Fidelity Growth Company Fund | 4651160 | -72330 | 31 июл 2020 г. |
| Vanguard Mid-Cap Index Fund | 2818670 | -19960 | 31 июл 2020 г. |
| Vanguard Extended Market Index Fund | 1606120 | -11997 | 31 июл 2020 г. |
| Vanguard Health Care Fund | 8573390 | -403027 | 30 июн 2020 г. |
| Dodge & Cox Stock Fund | 2735260 | -350000 | 30 июн 2020 г. |
| T. Rowe Price New Horizons Fund | 1316280 | -54800 | 30 июн 2020 г. |
| T. Rowe Price Mid-Cap Growth Fund | 1275000 | 900 | 30 июн 2020 г. |
| BB Biotech Fd | 1270000 | -190000 | 30 июн 2020 г. |
| T. Rowe Price Health Sciences Fund | 1215400 | -23231 | 30 июн 2020 г. |
Новостная лента
3 Pharma Stocks That Could See a Surge in Demand in 2023
InvestorPlace
24 апр 2023 г. в 15:55
As 2023 unfolds, the pharmaceutical space is blossoming with new opportunities, sparking curiosity for those looking to buy some pharma stocks. With the iShares Biotechnology ETF (NASDAQ: IBB ) ticking upward, for the most part, this year, investors who dive into pharma stocks need to capitalize on the sector's positive momentum.
These Are the Top 10 Holdings of Avoro Capital Advisors
24/7 Wall Street
17 апр 2023 г. в 22:54
Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
3 Growth Stocks That Could Disrupt the Healthcare Industry
InvestorPlace
13 мар 2023 г. в 15:29
Healthcare growth stocks are often sought out by investors looking for market disruptors. That's because these stocks can potentially deliver high revenue growth, earnings, and stock price.
Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues
Zacks Investment Research
24 февр 2023 г. в 10:32
Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly approved Amvuttra.
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 февр 2023 г. в 13:46
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President, Investor Relations and Corporate Communications Yvonne Greenstreet - Chief Executive Officer Tolga Tanguler - Chief Commercial Officer Pushkal Garg - Chief Medical Officer Jeff Poulton - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen David Lebowitz - Citi Tazeen Ahmad - Bank of America Securities Maury Raycroft - Jefferies Paul Matteis - Stifel Gena Wang - Barclays Luca Issi - RBC Myles Minter - William Blair Eliana Merle - UBS Operator Thank you for standing by and welcome to the Alnylam Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. As a reminder today's conference call is being recorded.